Natalizumab safe, effective in MS over longer periods

Natalizumab’s safety profile and low relapse rate in multiple sclerosis remain unchanged with up to five years of use, Australian-led research shows for the first time.

The large, multinational study looked at over 4,800 MS patients, 470 of whom had been taking natalizumab (Tysabri) for at least four years and the rest for at least two years.

“No new safety concerns were identified,” the authors wrote, with an overall incidence of progressive multifocal leucoencephelopathy (PML) that was